New therapy combined with immunology, molecular biology and medical technology for patients with peritoneal carcinosis

免疫学、分子生物学和医疗技术相结合的腹膜癌新疗法

基本信息

批准号：
12557106
负责人：
KATANO Mitsuo
金额：
$ 8.26万
依托单位：
KYUSHU UNIVERSITY
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B)
财政年份：
2000
资助国家：
日本
起止时间：
2000 至 2001
项目状态：
已结题

项目摘要

This study was focused on the development of new therapeutic strategy combined with immunology, molecular biology, and medical technology for poor prognostic patients with peritoneal carcinosis. Data obtained for duration of this study are as follows :(1) In order to develop new therapy and elucidate biological characteristics of peritoneal carcinosis, artificial tissues such as peritoneum, connective tissue, and lymphnodes were developed using various types of cells obtained from surgically resected specimens.(2) Using these developed artificial tissues, artificial carcinoma tissue similar to human scirrhous type-gastric carcinoma tissue was newly developed. In addition, a possible new therapeutic strategy for scirrhous carcinoma of the stomach, i.e., interferon-gamma therapy, was developed using this artificial carcinoma tissue.(3) New model of peritoneal carcinosis was developed using artificial peritoneum. New immunotherapy which is called "reconstruction therapy of immune surveillance system", for peritoneal carcinosis was developed using this new model.(4) Phase I study (19 patients) of "reconstruction therapy of immune surveillance system based on peripheral blood stem cell transplantation and dendritic cell (DC) vaccine for patients with pleural and peritoneal carcinosis" was almost completed.Experiments planned originally were not completely carried out. However, we newly developed several artificial tissues, including peritoneum, connective tissue, lymphnode, and carcinoma tissue, and we established new therapeutic strategies which are called "interferon-gamma therapy" and "reconstruction therapy of immune surveillance system". Especially, clinical application of "reconstruction therapy of immune surveillance system for patients with peritoneal carcinosis" started.

本研究的重点是结合免疫学、分子生物学和医疗技术为预后不良的腹膜癌患者开发新的治疗策略。本研究期间获得的数据如下：（1）为了开发新疗法并阐明腹膜癌的生物学特征，利用手术切除的各种类型的细胞开发了腹膜、结缔组织和淋巴结等人造组织(2)利用这些开发的人造组织，新开发出类似于人类硬质型胃癌组织的人造癌组织。此外，利用这种人造癌组织开发了一种可能的胃硬癌新治疗策略，即干扰素-γ疗法。(3)利用人造腹膜开发了腹膜癌的新模型。利用这一新模式，开发了针对腹膜癌的新型免疫疗法，即“免疫监视系统重建疗法”。(4)“基于外周血干细胞移植和免疫监视系统重建疗法”的I期研究（19例患者）用于胸膜和腹膜癌患者的树突状细胞（DC）疫苗”已基本完成。原计划的实验并未完全进行。然而，我们新开发了几种人工组织，包括腹膜、结缔组织、淋巴结和癌组织，并建立了新的治疗策略，称为“干扰素-γ疗法”和“免疫监视系统重建疗法”。特别是“腹膜癌患者免疫监视系统重建治疗”开始临床应用。